Please login to the form below

Not currently logged in

EU and UK pharma leaders appeal directly to Brexit negotiators

EFPIA, ABPI and BIA warn Michel Barnier and David Davies an unorderly withdrawal could hit medicine supplies


Pharma groups have warned chief Brexit negotiators Michel Barnier and David Davies that an unorderly withdrawal of the UK from the EU could wreak havoc with the supply of medicines.

Eight associations from the UK and Europe have written an open letter to the negotiators to plead for an early partnership agreement on medicines, saying that drugs could be "held either at border checks, in warehouses or manufacturing and/or subject to extensive retesting requirements".

Getting an early deal on medicines regulation "is the best way of ensuring that patients across Europe and the UK are able to continue to access safe and effective medicines and to ensure that there is no adverse impact on public health", say the industry bodies.

The letter was signed by the heads of the European Federation of Pharmaceutical Industries and Associations (EFPIA), EuropaBio, the Association of the British Pharmaceutical Industry (ABPI) and the BioIndustry Association (BIA) along with groups representing generic and over-the-counter drugs.

The UK and EU have already agreed a phased approach to the mammoth task of negotiation Brexit, and the pharma industry is pushing for the legal and regulatory aspects of the medicines trade to be included in the first wave to "avoid any adverse impact on public health and patient safety in both the EU-27 and UK after the UK leaves the EU".

Last week, UK health secretary Jeremy Hunt and business secretary Greg Clark said in a letter to the Financial Times that the UK "would like to find a way to continue to collaborate with the EU" on the regulation of medicines after 30 March 2019 - the date when the UK officially leaves the EU under the two-year Article 50 process.

The industry associations' letter welcomes that move and says "we would like to explore this possibility to maintain close regulatory ties between the EU and the UK and to begin these discussions immediately".

The letter emphasises that it's very much a two-way problem. Aside from the large number of medicines produced in the UK and destined for EU-wide distribution, the UK Medicines and Healthcare products Regulatory Agency (MHRA) makes a significant contribution to the current operations of the European Medicines Agency (EMA) - soon to move from its London base to an EU-27 home - and its withdrawal could hit capacity at the EU regulator.

"An implementation period that adequately reflects the time needed by pharmaceutical and biotech companies to transition to a new framework should be agreed on by negotiators," says the letter.

"This will allow companies time to make the necessary arrangements to avoid any unintended consequences on the availability of medicines."

Article by
Phil Taylor

13th July 2017

From: Regulatory



Subscribe to our email news alerts

Featured jobs


Add my company
Blue Latitude Health

Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...

Latest intelligence

Our Top 5 Pharma Picks From Cannes Lions
Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
The Evolving Role of the Sales Rep
The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
Measure your omnichannel maturity with our new tool
Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....